[View Original Text]

AIDOT (represented by Jae-hoon Jeong) announced on the 30th that it has obtained a domestic patent for a precise medical AI (Artificial Intelligence) solution, 'BIO dot AI,' which 

utilizes the microbiome for disease diagnosis and prediction.

AIDOT is a company currently developing and conducting validation for a chronic (alcoholic) liver disease diagnosis and prediction precision medical AI solution (BIO dot AI) as part of the innovation project fostering initiative in Gangwon Province Free Economic Zone. The company is currently preparing for clinical trials and obtaining approval from the Ministry of 

Food and Drug Safety.

This patent covers the technology of generating training data using the gut microbiome, not limited to chronic alcoholic liver disease, and a disease automatic diagnosis system. 

AIDOT emphasizes the significance of having broader patent rights than the functionalities of the ongoing 'BIO dot AI.' An AIDOT representative stated, "This patent protection 

extends not only to 'BIO dot AI' but also to future AI solutions utilizing the microbiome," and further added, "This means that AIDOT has taken the lead in the 

microbiome AI analysis market, making it difficult for latecomers to enter."

According to AIDOT, chronic liver diseases have high treatment success rates when diagnosed early. Conventional invasive methods such as liver tissue biopsy can cause pain and 

side effects. Non-invasive methods like CT (Computerized Tomography) and MRI (Magnetic Resonance Imaging) are cost-intensive and have lower sensitivity and specificity 

compared to liver tissue biopsy.

An AIDOT representative mentioned, "Microbiome genomic analysis AI solutions utilize patient-derived samples (feces) as in vitro diagnostic medical devices," and added, "It provides results with high sensitivity and specificity similar to liver tissue biopsy." Furthermore, they stated, "It has a competitive advantage in commercialization by reducing costs and 

detecting liver disease risks early without side effects."

AIDOT expects to commercialize the business not only through liver examinations via general and workplace health checkups that include stool tests but also by applying insurance 

coverage to make the tests more affordable. In recent years, there has been an increasing trend of conducting gut microbiome analysis for the purpose of dieting. 'BIO dot AI' is 

capable of providing reliable and precise analysis results for alcoholic liver disease, opening up possibilities for diverse business applications. Particularly, its ability to diagnose and 

predict alcoholic liver disease easily through fecal samples gives it an advantage to enter countries with a high prevalence of alcohol-related diseases, as explained by AIDOT.

Money Today / 10th. June, 2023 / Reporter Doo-ri Lee